TNFR2

TNFR2

TNFR2 Overview

Molecule Name
Tumor necrosis factor receptor superfamily member 1B
Synonyms
TNFRSF1B,CD120b,TBPII,TNF-R-II,TNF-R75,TNFBR,TNFR1B,TNFR2,TNFR80,p75,p75TNFR
Drug Development Progress
Drugs in Clinical Trials8
Approved Drugs1
Highest Development StageApproved
Target Synonym
TNFR-II,TNFR80,TNF-RII,p80 TNF-alpha receptor,p75,Tumor necrosis factor receptor 2,Etanercept,TBP-2,Tumor necrosis factor receptor type II,TBPII,CD120b,TNF-R-II,CD120b Antigen,Tumor Necrosis Factor Beta Receptor,Soluble TNFR1B Variant 1,Tumor Necrosis Factor Binding Protein 2,TNFBR,TNF Receptor Superfamily Member 1B,TNFR2,P75 TNF Receptor,P75TNFR,TNFR1B,Tumor Necrosis Factor Receptor Superfamily, Member 1B,TNF-R75,TNF-R2
Background
TNF RI is also known as the p60 or p55 TNFR) and TNF RII (the p75 or p80 TNFR) are two distinct type I transmembrane glycoproteins that bind TNF with highaffinity.Both RI and RII are prototypic members of the TNF receptor superfamily and have been designated TNFRSF1A and TNFRSF1B, respectively. Human TNF RII cDNA encodes a 461 amino acid (aa) residue precursor protein with a 22 aa putative signal peptide, a 235 aa extracellular domain, a 20 aa transmembrane domain and a 174 aa cytoplasmic domain. TNFRII is expressed in fetal brain. The protein is produced naturally as a soluble form (sTNFRII). The soluble receptor inhibits TNFα action by competing with cell surface receptors in binding TNFα, thereby blocking its biologic effects. TNFRII is strongly expressed at the cartilage–pannus junction, and plays a major role in a subset of families with multiple cases of rheumatoid arthritis (RA). Further, high plasma levels of sTNFRII were significantly associated with increased incidence of coronary heart disease, independent of established cardiovascular risk factors, and seems to be useful for monitoring the inflammatory activity of sarcoidosis.

TNFR2 Product List

No Data
You Have Viewed 0 Of 0 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
LBL-019LBL-019Phase 2 ClinicalNanjing Leadsbiolabs Co Ltd
Neoplasms
Details
BI-1910BI-1910Phase 2 ClinicalBioinvent International Ab
Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Solid tumours
Details
BITR-2101BITR-2101; BIR-2101; BITT2101; BITT-2101Phase 1 ClinicalBoston Immune Technologies & Therapeutics
Infections; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell, Peripheral; Neoplasms
Details
TRB-061TRB-061Phase 1 ClinicalTrex Bio Inc
Colitis; Dermatitis; Dermatitis, Atopic
Details
NBL-020Phase 1 ClinicalShanghai Xinshi Biological Medicine Co Ltd
Neoplasms; Solid tumours
Details
BC-011BC-011Phase 1 ClinicalDragonboat Biopharmaceutical
Solid tumours
Details
SIM1811-03SIM1811-03; SIM0235; SIM-235Phase 1 ClinicalJiangsu Simcere Pharmaceutical Co Ltd
Lymphoma, T-Cell, Cutaneous; Neoplasms; Solid tumours
Details
EmunkitugHFB-2003; HFB-200301Phase 1 ClinicalHiFiBiO Therapeutics
Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Germinoma; Melanoma; Mesothelioma; Neoplasm Metastasis; Neoplasms; Sarcoma; Skin Melanoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Testicular Neoplasms; Uterine Cervical Neoplasms
Details

Marketed Drug Information

English NameResearch CodeHighest Development StageCompanyEarliest Brand NameEarliest Approval CountryEarliest IndicationEarliest Approval CompanyEarliest Approval DateIndicationClinical Trial
Recombinant human type II tumor necrosis factor receptor-antibody fusion protein(Hisun Biological)ApprovedHisun Biopharmaceutical Co LtdMainland ChinaSpondylitis, Ankylosing; Psoriasis; Arthritis, RheumatoidHisun Biopharmaceutical Co Ltd2015-04-09
Arthritis, Rheumatoid; Psoriasis; Spondylitis, Ankylosing
Details